-
The medicine is one of the few to win regulatory approval as a treatment for the disease, but has fallen out of favor with the health authority.
-
Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices.
-
Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable.